UBS raised its 2008 EPS forecast by $0.10.
UBS Securities has raised its earnings per share forecast for Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) on expectations that it will launch generic Risperdal today. UBS analyst Ricky Goldwasser predicts an extra $0.10 earnings per share in 2008, assuming that Teva wins a 45% market share and that generic Risperdal sells at half the price of the brand drug. He adds that each additional 5% market share will add $0.01-0.02 to Teva's earnings per share.
UBS gives Teva a "Buy" recommendation
The brand product, made by Johnson & Johnson (NYSE: JNJ) unit Janssen, has $2.7 billion in annual sales. Risperdal is used to treat schizophrenia.
Published by Globes [online], Israel business news - www.globes-online.com - on June 29, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008